Editorial
Volume 2 Issue 1
Anubha Bajaj*
June 09, 2023
Abstract
Adrenocortical carcinoma is an exceptionally discerned, malignant, endocrine, epithelial tumour emerging from adrenal cortical cells. The heterogeneous neoplasm may be engendered due to overexpression of IGF2 and is associated with significant mortality. Majority of neoplasms appear as sporadic lesions although may demonstrate diverse syndromic settings. Prognostic outcomes are contingent to age of incriminated subject, clinical representation, tumour stage, precise histological variant and molecular or genomic characteristics of the neoplasm.
Additionally designated as adrenal cortical carcinoma (ACC), conventional subtype of adrenocortical carcinoma, adrenal cortical adenocarcinoma or malignant adrenal cortical tumour, the neoplasm configures around ~6.8% of primary adrenal neoplasms. Median age of disease occurrence is ~55 years although no age of disease emergence is exempt. A bimodal distribution of disease is encountered with peak occurrence within first decade and fifth decade. Caucasians are commonly implicated. A female preponderance is observed with male to female proportion of 1:1.5 - 2.5. Adrenocortical carcinoma is predominantly sporadic although ~10% instances arise within syndromic settings (1,2).
References